Since Mbd2-depleted mice are viable and fertile, testing whether targeting Mbd2 and/or its ability to bind methylated DNA produces a similar anticancer effect in patients with breast cancer to reduce cancer-associated morbidity and mortality would be similarly attractive. Here, MBD2 is linked to breast carcinoma.